Randox Laboratories

Metabolic Syndrome Arrays

View Brochure:
Metabolic Array

For simultaneous determination of analytes associated with metabolic syndrome and related disorders

About Randox Metabolic Syndrome Arrays

Metabolic Syndrome is a clustering of cardiovascular risk factors and with approximately 20-25% of adults affected, it is highly prevalent. It is estimated that having Metabolic Syndrome leads to a person being three times more likely to have a stroke or heart attack and five times more likely to develop diabetes. However, the pathophysiological processes leading to Metabolic Syndrome remain unclear, with no universally accepted definition.

Metabolic Syndrome has been defined by various different expert groups and associations each using different sets of criteria, which reflect the contrasting views on the pathological mechanisms and clinical application. However, the International Diabetes Federation (IDF) have proposed a worldwide definition which states that in order to have Metabolic Syndrome, a person must have central obesity plus two of the following four factors; raised triglycerides, reduced HDL cholesterol, raised blood pressure and raised fasting plasma glucose.

Benefits of Randox Metabolic Syndrome Array

Multiple assays from one sample using Biochip Array Technology
Analytes have been carefully selected for application to a wide range of clinical research studies
Suitable for both serum and plasma samples
Small sample volume - 100 μl to measure all analytes on each array
Very efficient use of highly valuable patient sample banks
Biochips are ready to use, saving time and resources
Semi-automated analyser requiring minimal maintenance
Quick time to results
Multi-analyte controls and calibrators available
Excellent assay performance
Range of associated arrays available for comprehensive studies
No none-specific aggregation associated with multi-analyte bead assays